None listed
Conditions
Interventions
Intervention1: NAM:
NAM: 36.5mg
NAM - 110 mg
NAM- 219 mg
Control Intervention1: NMN: NMN: 100 mg
NMN: 300 mg
NMN: 600 mg
Sponsors
Dr. Chikkalingaiah Siddegowda
Eligibility
Inclusion criteria
Inclusion criteria: -Adult healthy male/females aged 40 to 65 years. -Participants with Body Mass Index (BMI) between 18.5 and 35 kg/m2. -Participants who are willing to provide written Informed Consent for participating in the study -Participants who are able to follow verbal and written study directions. -Participants must be willing to agree to use effective contraceptive methods while on treatment and for 3 months after the completion of study. -Participants willing to administer assigned dietary supplements for the study duration. -Participants willing to avoid nutritional yeast, whey proteins, energy drinks, dairy products, grapefruit, grapefruit juice, and alcohol for 7 days prior to enrollment and throughout the study period.
Exclusion criteria
Exclusion criteria: -Participants using prescription or over-the-counter nicotinic acid, niacin, nicotinamide mononucleotide, nicotinamide riboside, or any other NAD+ precursors, Vitamin B3, or its derivatives within 14 days prior to enrolment and throughout the study duration. -Participants using any statin drugs. -Participants having used any tobacco product or used a recreational drug in the past 6 months. -Participants having abnormal screening laboratory test values or other lab test result(s) that would preclude study participation in the judgment of the investigator. -Participants with documented presence of atherosclerotic disease and/or cardiopulmonary disease. -Participants with a medical history or active diagnosis of chronic diseases or conditions affecting the urinary, cardiovascular, neuroendocrine (including diabetes), immune, central nervous, hematopoietic, gastrointestinal, hepatic, or visual systems, hereditary diseases, or other significant systemic disorders, as well as those with acute infectious diseases within 28 days prior to the study, known allergies or positive test results for sexually transmitted infections such as HIV, hepatitis B, hepatitis C, or syphilis. -Participants with history of drug or alcohol abuse within the past 6 months -Participants who smoked more than 10 cigarettes a day within one year before screening. -Participants with history of unstable depression or mental illness within the last 6 months for which the investigator believes could impact the participants ability to comply with study requirements. -Participants unwilling to discontinue use of conventional multivitamin/mineral or other supplements at least two weeks prior to the start of study. -Participants who are currently participating in or planning to begin a weight loss diet during the study period. -Participants who chronically use over-the-counter medication which would interfere with study endpoints. -Participants whose lifestyle or schedule incompatible with the study protocol. -Participants with known hypersensitivity to the drug components used during the study. -Female participants with positive result for urinary beta human chorionic gonadotropin or gestation period or breastfeeding. -Other diseases or medications, according to the investigator, that would interfere directly in the results of the study or jeopardize the health of the participant. -Currently, or within the past 30 days, enrolled in a different clinical investigation. -Inability to provide a venous blood sample. -Patients with a current diagnosis of any form of cancer within the past 5 years, regardless of disease stage or treatment status, are ineligible for participation in this clinical trial. Any history of cancer within this timeframe must be documented and confirmed through medical records or pathology reports.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentrations of the following parameters: NAD+, NMN, NAM, MeNam, 2-Pyr, 4-Pyr Erythrocyte concentrations of NAD+Timepoint: [Time frame: 0h, 1h, 2h, 4h, 8h, 12h, 24h] | — |
Secondary
| Measure | Time frame |
|---|---|
| Urine concentrations of the following parameters: NAM, MeNam, 2-Pyr, 4-PyrTimepoint: [Time frame: 0h, 1h, 2h, 4h, 8h, 12h, 24h] | — |
Countries
India
Contacts
Public ContactDr Chikkalingaiah Siddegowda
Medstar Specialist Hospital
Outcome results
None listed